Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression

Xia Zhang(Institute of Biophysics), Yang Zhang(Guangdong Testing Institute for Product Quality Supervision), Bin Zhang(Harbin Medical University), Jie Liu(University of Michigan), Minmin Li(Shandong Tumor Hospital), Changzheng Li(Sun Yat-sen University), Bo Tang(Guangxi Medical University), Jiwei Liu(Mongolian University of Science and Technology), Bao Song(Shandong Tumor Hospital), Zhehai Wang(Shandong Tumor Hospital), Shu Fang(Peking University), Wei Dong(Kunming University of Science and Technology)
Scientific Reports
February 3, 2015
10.1038/srep07835
Cited by 29

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models
|Nature Biotechnology|2010|918
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Genomic Variation in Natural Populations of<i>Drosophila melanogaster</i>
|Genetics|2012|393
RETRACTED ARTICLE: m6A demethylase ALKBH5 inhibits pancreatic cancer tumorigenesis by decreasing WIF-1 RNA methylation and mediating Wnt signaling
|Molecular Cancer|2020|358